References
-
1
Aliyev NA, Aliyev ZN.
Application of glycine in acute alcohol hallucinosis.
Human Psychopharmacol.
2005;
20
591-594
-
2 Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie/AMDP .Das AMDP-System: Manual zur Dokumentation psychiatrischer Befunde. 5th revised edn. Göttingen, Bern, Berlin, Heidelberg, New York, Hogrefe 2005
-
3
Borg S, Kvande H, Valverius P.
Clinical conditions and central dopamine metabolism in alcoholics during acute withdrawal under treatment with different pharmacological agents.
Psychopharmacology.
1986;
88
12
-
4
Caton CLM, Drake RE, Hasin D, Dominguez B, Shrout PE, Samet S, Schanzer B.
Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses.
Arch Gen Psychiatry.
2005;
62
137-145
-
5
De Millas W, Haasen C.
Treatment of alcohol hallucinosis with risperidone.
Am J Addict.
2007;
16
249-250
-
6
Fadda F, Mosca E, Colombo G, Gessa GL.
Effects of spontaneous ingestion of ethanol on brain dopamine metabolism.
Life Sci.
1989;
44
281
-
7
Glass IB.
Alcohol hallucinosis: a psychiatric enigma - 1. the development of an idea.
Br J Addiction.
1989;
84
29-41
-
8
Glass IB.
Alcohol hallucinosis: a psychiatric enigma - 2. the follow-up studies.
Br J Addict.
1989;
84
151-164
-
9 Guy W, Ban TA. The AMDP-SYSTEM. Manual for the Assessment and Documentation of Psychopathology. Berlin, Heidelberg, New York, Springer 1982
-
10
Hermann D, Heinz A, Croissant B, Mann K.
Provoked recurrence of alcohol hallucinosis - remission with additive amisulpride medication. A case report.
Pharmacopsychiatry.
2004;
37
90-92
-
11
Kitabayashi Y, Narumoto J, Shibata K, Ueda H, Fukui K.
Neuropsychiatric background of alcohol hallucinosis: a SPECT study.
J Neuropsychiatry Clin Neurosci.
2007;
19
85
-
12
Soyka M.
Psychopathological characteristics in alcohol hallucinosis and paranoid schizophrenia.
Acta Psychiatrica Scandinavica.
1990;
81
255-259
-
13
Soyka M, Botschev C, Völcker A.
Neuroleptic treatment in alcohol hallucinosis: no evidence for increased seizure risk.
J Clin Psychopharmacol.
1992;
12
66-67
-
14
Soyka M.
Pathophysiologic mechanisms possibly involved in the development of alcohol hallucinosis.
Addiction.
1995;
90
289-290
-
15
Soyka M, Wegner U, Moeller H-J.
Risperidone in treatment-refractory chronic alcohol hallucinosis.
Pharmacopsychiatry.
1997;
30
135-136
-
16
Soyka M Dresel S, Horak M, Rüther T, Tatsch K.
PET and SPECT findings in alcohol hallucinosis: Case report and super-brief review of the pathophysiology of this syndrome.
World J Biol Psychiatry.
2000;
1
215-218
-
17
Soyka M, Zetzsche T, Dresel S, Tatsch K.
FDG-PET and IBZM-SPECT suggest reduced thalamic activity but no dopaminergic dysfunction in chronic alcohol hallucinosis.
J Neuropsychiatry Clin Neurosci.
2000;
12
287-288
-
18
Soyka M, Koch W, Tatsch K.
Thalamic hypofunction in alcohol hallucinosis: FDG PET findings.
Psychiatry Res Neuroimaging.
2005;
30
259-262
-
19
Surawicz FG.
Alcoholic hallucinosis: a missed diagnosis.
Can J Psychiatry.
1980;
25
57-63
-
20
Tsuang JW, Irwin MR, Smith TL, Schuckit MA.
Characteristics of men with alcohol hallucinosis.
Addiction.
1994;
89
73-78
-
21
Victor M, Adams RD.
Effects of alcohol on the nervous system.
Res Pub Assoc Res Nerv Ment Dis.
1953;
32
526
Correspondence
Prof. Dr. M. SoykaMD
Psychiatric Hospital Meiringen
P.O. Box 612
3860 Meiringen
Switzerland
Phone: +41/033/972 82 95
Fax: +41/033/972 82 91
Email: michael.soyka@pm-klinik.ch
